Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Has Average Target Price of $22.59

Key Points

• Analysts collectively rate Sarepta Therapeutics “Reduce.” Among 21 covering firms, eight recommend selling, six advise holding and seven recommend buying; the average 12-month price target is $22.59.
• Sarepta shares opened at $17.44, down 2.3%, with a market capitalization of approximately $1.84 billion. The stock has traded between $14.68 and $24.68 over the past year.
• The company exceeded quarterly earnings and revenue expectations, reporting $0.64 in adjusted EPS and $401.25 million in revenue, but revenue fell 34.3% year over year and Sarepta remained unprofitable overall.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) has been given an average rating of "Reduce" by the twenty-one research firms that are presently covering the company, MarketBeat.com reports. Eight research analysts have rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $22.59.

Several equities analysts have recently weighed in on SRPT shares. Wall Street Zen cut Sarepta Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. Weiss Ratings lowered Sarepta Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Thursday, September 24th. Wolfe Research upgraded Sarepta Therapeutics from a "peer perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a report on Thursday, July 9th. William Blair raised Sarepta Therapeutics to a "hold" rating in a research report on Wednesday, September 23rd. Finally, JPMorgan Chase & Co. decreased their price target on Sarepta Therapeutics from $23.00 to $20.00 and set a "neutral" rating for the company in a research note on Wednesday, September 30th.

Sarepta Therapeutics Stock Down 2.3%

Sarepta Therapeutics stock opened at $17.44 on Tuesday. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55. Sarepta Therapeutics has a 1-year low of $14.68 and a 1-year high of $24.68. The company has a fifty day simple moving average of $19.24 and a 200 day simple moving average of $18.83. The company has a market cap of $1.84 billion, a P/E ratio of -6.01, a price-to-earnings-growth ratio of 0.28 and a beta of 0.38.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The firm had revenue of $401.25 million for the quarter, compared to analysts' expectations of $366.39 million. During the same period in the previous year, the firm posted $2.02 EPS. The company's revenue for the quarter was down 34.3% on a year-over-year basis. Research analysts anticipate that Sarepta Therapeutics will post 3.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SRPT. PNC Financial Services Group Inc. raised its position in Sarepta Therapeutics by 7.8% during the first quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company's stock worth $190,000 after acquiring an additional 636 shares in the last quarter. Public Employees Retirement System of Ohio lifted its stake in Sarepta Therapeutics by 3.1% in the first quarter. Public Employees Retirement System of Ohio now owns 28,787 shares of the biotechnology company's stock valued at $626,000 after acquiring an additional 875 shares during the last quarter. Baird Financial Group Inc. grew its position in shares of Sarepta Therapeutics by 7.6% in the 2nd quarter. Baird Financial Group Inc. now owns 12,805 shares of the biotechnology company's stock valued at $230,000 after acquiring an additional 901 shares during the period. Meeder Asset Management Inc. bought a new position in shares of Sarepta Therapeutics in the 2nd quarter valued at about $27,000. Finally, Rockefeller Capital Management L.P. grew its position in shares of Sarepta Therapeutics by 98.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 4,104 shares of the biotechnology company's stock valued at $88,000 after acquiring an additional 2,034 shares during the period. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc NASDAQ: SRPT is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs include RNA-based therapies, gene therapy and other genetic medicine approaches designed to address the underlying causes of serious genetic disorders.

The company's primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for certain patients with DMD mutations, as well as Elevidys, a gene therapy for eligible patients with Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.